CSL Vifor warns Tavneos exit from Europe will cut revenue by about 25%
read at Endpoints ↗RegulatoryNegative
CSL Vifor’s parent company CSL Limited said the withdrawal of the drug Tavneos from the European market creates a significant headwind for sales.
The company expects its revenue to fall by roughly a quarter in the upcoming fiscal period as a result of the pullback.
The development underscores the firm’s dependence on Tavneos in Europe and may force it to look for other growth avenues.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “CSL calls Tavneos withdrawal in Europe a 'significant headwind' for sales”
read at Endpoints ↗78 words · retrieved Aug 18
comments(0)
5-min edit window · permanent after that